




The relative strengths and weaknesses of Paratek Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 136% points. The greatest weakness of Paratek Pharmaceuticals Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 372%, being 118% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	101,329
Cost of Goods Sold	0
Intangible Assets	5,643
Liabilities, Current	3,741
Liabilities, Non-Current	3,592
Other Assets	2,946
Other Compr. Net Income	0
Other Expenses	1,278
Other Liabilities	7,410
Other Net Income	-5,695
Other Revenues	0
Property and Equipment	49
Research and Development	5,014
Selling, General and Administrative Expense	5,848

Output Variable	Value in 1000 USD
Assets	109,967
Liabilities	14,743
Expenses	12,140
Revenues	0
Stockholders Equity	95,224
Net Income	-17,835
Comprehensive Net Income	-17,835
BaseVar	71,272
ECR before LimitedLiability	304%
Economic Capital Ratio	372%